$TGT reported 3.8% comparable-sales growth, an 8.7% increase in digital comparable sales and more than 25% growth in same-day delivery.
The retail turnaround continues gaining weight.
#TGT#RetailStocks#Earnings
$VOYG won a Space Force contract to develop secure space-to-space communications across multiple orbits.
The next satellite networks must communicate with each other—not only with Earth.
#VOYG#SpaceStocks#DefenseTech
$CAPR has a pulse again.
The FDA agreed to review new 24-month deramiocel data. Nothing is approved yet, but the regulatory door remains open.
#CAPR#BiotechStocks#DMD
$VRTX expanded CASGEVY’s approval to children as young as two, opening the one-time genetic therapy to approximately 5,500 additional U.S. patients.
#VRTX#GeneTherapy#HealthcareStocks
$REPL secured FDA approval for its first commercial product after a difficult regulatory fight.
Biotech can change direction with one decision.
#REPL#BiotechStocks#FDA
$RDDT grew Q2 revenue 61% while delivering a 31% net margin.
Growth and profitability arriving together. That combination is hard to ignore.
#RDDT#GrowthStocks#SocialMediaStocks
$MSGE quietly crossed $1B in annual revenue.
Fiscal 2026 revenue increased 13%, operating income rose 16% and the live-entertainment engine keeps getting stronger.
Sometimes the cleanest growth stories are hiding in plain sight.
#MSGE#EntertainmentStocks
Not every growth story needs a server rack.
$BIRK posted 15% constant-currency revenue growth and raised its full-year outlook.
A recognizable global brand, strong direct-to-consumer demand and pricing power. Simple businesses can still produce powerful numbers.
#BIRK#Consumer
$CSCO booked $9.3B in AI-infrastructure orders during fiscal 2026 and expects roughly $7.5B in related revenue next year.
The old networking giant is becoming a serious picks-and-shovels name for the AI buildout.
#CSCO#AIInfrastructure#TechStocks
Moderna $MRNA now has its fifth approved product.
The FDA approved mFLUSIVA for adults aged 50 and older, making it the first mRNA-based influenza vaccine approved in the United States.
#MRNA#Biotech#FDA
Drilling earns attention when the step-outs expand the system instead of producing another isolated headline.
Goliath Resources $GOT.V $GOTRF reported up to 10.32 g/t gold over 6.00 metres inside the newly expanded Golden Gate area.
#GoldStocks#MiningStocks#GOT
$MITK IS TURNING DIGITAL IDENTITY INTO REAL GROWTH
Mitek Systems reported fiscal Q3 revenue of $54M, up 18% year over year.
#MITK#Cybersecurity#Fintech
$PINS reported Q2 revenue of $1.18B, up 18%, while monthly active users reached a record 640 million.
A massive audience and growing AI-powered shopping and discovery tools, $PINS continues strengthening the connection between user intent and digital commerce.
#PINS#TechStocks
DHT reported Q2 shipping revenue of $284.8 million, more than double the $127.9 million generated during the same quarter last year.
Adjusted EBITDA reached $231 million, while net profit increased to $198.3 million, or $1.23 per share.
#DHT#ShippingStocks#Dividends
Shopify reported 34% year-over-year revenue growth for Q2 2026 while producing an 18% free-cash-flow margin.
The company delivered growth above 30% across gross merchandise volume, revenue, gross profit and free cash flow.
#SHOP#Earnings#TechStocks
Big order for $MDA today.
The company picked up another $474M of work tied to the Telesat Lightspeed constellation. That means more satellites, added military capability and a larger production run.
Real contracts continue to drive this space story.
#MDA#SpaceStocks
Okay, $TSEM had a pretty serious quarter.
Revenue hit a record $460M, up 24% year over year, and net profit nearly doubled to $91M. Now they’re guiding for another record next quarter at $520M.
Hard to argue with numbers moving like that.
#TSEM#Semiconductors
Regulatory walls rarely fall in one strike. $REPL earned a 10–3 FDA advisory vote that IGNYTE efficacy results for RP1 were evaluable and clinically meaningful. It is not approval, but after a bruising path, the odds look different than they did before the vote. #REPL#Biotech
One loud transaction can distort a month. Six straight months are harder to ignore. $OWLS reported July payment volume up 107.6% and transaction count up 109.5%, while enterprise clients climbed to 79. Adoption is leaving footprints in the data. #OWLS#Fintech